Article
Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance.
Blood advances - 25 Oct 2022
Blombery Piers, Thompson Ella R, Lew Thomas E, Tiong Ing Soo, Bennett Rory, Cheah Chan Y, Lewis Katharine Louise, Handunnetti Sasanka M, Tang Chloe Pek Sang, Roberts Andrew, Seymour John F, Tam Constantine S
Abstract excerpt
The covalent Bruton's tyrosine kinase inhibitors (BTKis) are highly effective for the treatment of chronic lymphocytic leukemia (CLL). The dominant resistance mechanism observed with the BTKi ibrutinib is the development of BTK Cys481 codon mutations. Whether a similar resistance mutation profile exists for the newer-generation, more selective BTKi zanubrutinib is unknown. In samples referred for diagnostic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.